OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers
Rebecca Kristeleit, Alexandra Léary, Ana Oaknin, et al.
British Journal of Cancer (2024) Vol. 131, Iss. 5, pp. 820-831
Open Access | Times Cited: 8
Rebecca Kristeleit, Alexandra Léary, Ana Oaknin, et al.
British Journal of Cancer (2024) Vol. 131, Iss. 5, pp. 820-831
Open Access | Times Cited: 8
Showing 8 citing articles:
Tailored therapies for triple-negative breast cancer: current landscape and future perceptions
Yumna Khan, Sana Rizvi, Ali Raza, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access | Times Cited: 2
Yumna Khan, Sana Rizvi, Ali Raza, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access | Times Cited: 2
cGAS/STING signaling pathway in gynecological malignancies: From molecular mechanisms to therapeutic values
Danyang Zhang, Bingxue Zhang
Frontiers in Immunology (2025) Vol. 16
Open Access | Times Cited: 1
Danyang Zhang, Bingxue Zhang
Frontiers in Immunology (2025) Vol. 16
Open Access | Times Cited: 1
The Histomorphology to Molecular Transition: Exploring the Genomic Landscape of Poorly Differentiated Epithelial Endometrial Cancers
Thulo Molefi, Lloyd Mabonga, Rodney Hull, et al.
Cells (2025) Vol. 14, Iss. 5, pp. 382-382
Open Access | Times Cited: 1
Thulo Molefi, Lloyd Mabonga, Rodney Hull, et al.
Cells (2025) Vol. 14, Iss. 5, pp. 382-382
Open Access | Times Cited: 1
Characteristics of the Immune Microenvironment and Progress in Immunotherapy for Triple-Negative Breast Cancer
书韬 贾
World Journal of Cancer Research (2025) Vol. 15, Iss. 01, pp. 24-38
Closed Access
书韬 贾
World Journal of Cancer Research (2025) Vol. 15, Iss. 01, pp. 24-38
Closed Access
Besides the front-line maintenance therapy, is any positive impact of poly (ADP-ribose) polymerase (PARP) inhibitors on recurrent high-grade ovarian cancer?
Yiu-Tai Li, Peng‐Hui Wang
Taiwanese Journal of Obstetrics and Gynecology (2024) Vol. 63, Iss. 5, pp. 599-600
Open Access | Times Cited: 3
Yiu-Tai Li, Peng‐Hui Wang
Taiwanese Journal of Obstetrics and Gynecology (2024) Vol. 63, Iss. 5, pp. 599-600
Open Access | Times Cited: 3
Novel clinical potential of poly (ADP‑ribose) polymerase inhibitors in triple‑negative breast cancer: Mechanistic insights and clinical applications (Review)
Han Yu, Lei Wei
Oncology Letters (2025) Vol. 29, Iss. 5, pp. 1-14
Open Access
Han Yu, Lei Wei
Oncology Letters (2025) Vol. 29, Iss. 5, pp. 1-14
Open Access
Impact of Molecular Profiling on Therapy Management in Breast Cancer
Flavia Ultimescu, Ariana Hudiță, Daniela Elena Popa, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 17, pp. 4995-4995
Open Access | Times Cited: 2
Flavia Ultimescu, Ariana Hudiță, Daniela Elena Popa, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 17, pp. 4995-4995
Open Access | Times Cited: 2
Advancements in Clinical Research and Emerging Therapies for Triple-Negative Breast Cancer Treatment
Lili Xu, Pengtao Xu, Jingsong Wang, et al.
European Journal of Pharmacology (2024), pp. 177202-177202
Closed Access | Times Cited: 1
Lili Xu, Pengtao Xu, Jingsong Wang, et al.
European Journal of Pharmacology (2024), pp. 177202-177202
Closed Access | Times Cited: 1
